Treatment strategies and outcome in relapsed peripheral T-cell lymphoma:results from the Netherlands Cancer Registry

Optimal treatment in patients with refractory or relapsed peripheral T-cell lymphomas (R/R T-NHLs) is unknown. In this population-based study, outcomes in R/R peripheral T-cell lymphoma not otherwise specified (PTCL NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic lymphoma kinase-positive (ALK + ) and ALK-negative (ALK – ) anaplastic large cell lymphoma (ALCL) were evaluated. Patients with PTCL NOS, AITL, ALK + ALCL, and ALK – ALCL (≥18 years) diagnosed in 2014 to 2019 were identified using the Netherlands Cancer Registry. End points were overall response rate (ORR), progression... Mehr ...

Verfasser: Brink, Mirian
Huisman, Francien
Meeuwes, Frederik Okko
van der Poel, Marjolein W M
Kersten, Marie José
Wondergem, Marielle J
Bohmer, Lara H
Woei-A-Jin, F J Sherida H
Visser, Otto J
Oostvogels, Rimke
Jansen, Patty M
Diepstra, Arjan
Snijders, Tjeerd J F
Huls, Gerwin A
Vermaat, Joost S P
Plattel, Wouter J
Nijland, Marcel
Dokumenttyp: Artikel
Erscheinungsdatum: 2024
Reihe/Periodikum: Brink , M , Huisman , F , Meeuwes , F O , van der Poel , M W M , Kersten , M J , Wondergem , M J , Bohmer , L H , Woei-A-Jin , F J S H , Visser , O J , Oostvogels , R , Jansen , P M , Diepstra , A , Snijders , T J F , Huls , G A , Vermaat , J S P , Plattel , W J & Nijland , M 2024 , ' Treatment strategies and outcome in relapsed peripheral T-cell lymphoma : results from the Netherlands Cancer Registry ' , Blood advances , vol. 8 , no. 14 , pp. 3619-3628 . https://doi.org/10.1182/bloodadvances.2023012531
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29186816
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://cris.maastrichtuniversity.nl/en/publications/44856c8c-6dae-4502-b3b5-2c600b7f0cda

Optimal treatment in patients with refractory or relapsed peripheral T-cell lymphomas (R/R T-NHLs) is unknown. In this population-based study, outcomes in R/R peripheral T-cell lymphoma not otherwise specified (PTCL NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic lymphoma kinase-positive (ALK + ) and ALK-negative (ALK – ) anaplastic large cell lymphoma (ALCL) were evaluated. Patients with PTCL NOS, AITL, ALK + ALCL, and ALK – ALCL (≥18 years) diagnosed in 2014 to 2019 were identified using the Netherlands Cancer Registry. End points were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). The 2-year PFS of 821 patients was 57%. Among 311 patients with a relapse, 243 received second-line treatment: 44% received salvage chemotherapy, 20% received brentuximab vedotin (BV), and 36% received other treatment. In third-line treatment, BV was most commonly used (38%). ORR after second-line treatment was 47%. Two-year PFS and OS after relapse were 25% and 34%, respectively. The risk of second relapse was negatively affected by early relapse (<12 months after diagnosis), whereas BV reduced this risk compared with salvage chemotherapy. Reduced risk of relapse was independent of histological subtype. The best outcomes were observed for patients treated with salvage chemotherapy receiving consolidative autologous and allogeneic stem cell transplantation (SCT) (2-year OS 68%), patients treated with BV achieving a second complete remission (2-year OS 74%) and patients with allogeneic SCT (2-year OS 60%). The risk of second relapse was significantly lower for patients with R/R T-NHL treated with BV compared with patients treated with salvage chemotherapy, and this was irrespective of subtype. Therefore, the use of salvage chemotherapy for patients with R/R T-NHL is challenged.